US 11,840,559 B2
Glucagon-receptor selective polypeptides and methods of use thereof
William Blackwell, Research Triangle Park, NC (US); Ved P. Srivastava, Research Triangle Park, NC (US); Mark A. Paulik, Research Triangle Park, NC (US); Andrew Young, Research Triangle Park, NC (US); Robert Neil Hunter, III, Boston, MA (US); and Steven Thomas Dock, Boston, MA (US)
Assigned to i2o Therapeutics, Inc., Cambridge, MA (US)
Filed by Intarcia Therapeutics Inc., Boston, MA (US)
Filed on Nov. 30, 2021, as Appl. No. 17/538,507.
Application 17/538,507 is a continuation of application No. 16/667,502, filed on Oct. 29, 2019, granted, now 11,214,607.
Application 16/667,502 is a continuation of application No. 15/595,809, filed on May 15, 2017, granted, now 10,501,517, issued on Dec. 10, 2019.
Claims priority of provisional application 62/420,937, filed on Nov. 11, 2016.
Claims priority of provisional application 62/414,146, filed on Oct. 28, 2016.
Claims priority of provisional application 62/337,005, filed on May 16, 2016.
Prior Publication US 2022/0332781 A1, Oct. 20, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/605 (2006.01); C07K 14/00 (2006.01); A61K 38/26 (2006.01); A61K 9/00 (2006.01); A61M 5/142 (2006.01); A61M 31/00 (2006.01); A61M 5/145 (2006.01)
CPC C07K 14/605 (2013.01) [A61K 9/0004 (2013.01); A61K 38/26 (2013.01); C07K 14/00 (2013.01); A61M 5/14276 (2013.01); A61M 31/002 (2013.01); A61M 2005/14513 (2013.01)] 19 Claims
 
1. An isolated polypeptide comprising the amino acid sequence:
(SEQ ID NO: 151)
X1SX3GTFTSDX10SKYLDX16X17X18AQX21FVX24WLEDEPX31SX33X34
PPPS-OH,
or a pharmaceutically acceptable salt thereof, wherein:
X1=Y or W;
X3=H or Q;
X10=Y or K;
X16=A, S, Aib, or K;
X17=A, K, or Aib;
X18=S or R;
X21=E or K;
X24=I, Aib, or K;
X31=S or K;
X33=G or K; and
X34=A or S.